10-Q: Tyra Biosciences Reports Q1 2025 Financial Results, Advances Clinical Programs

Tyra Biosciences reports a net loss for Q1 2025, but anticipates existing funds will support operations through at least 2027 as it progresses its clinical-stage programs.

Summary

• Tyra Biosciences, a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025.
• The company is focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.
• Tyra's lead program, TYRA-300, is being evaluated in Phase 2 studies for bladder cancer and skeletal conditions.
• TYRA-200, an FGFR1/2/3 inhibitor, is in Phase 1 clinical study for intrahepatic cholangiocarcinoma (ICC).
• TYRA-430, targeting the FGF19 pathway, has commenced patient dosing in a Phase 1 study for hepatocellular carcinoma (HCC) and other solid tumors.
• The company's net loss for the three months ended March 31, 2025, was $28.1 million, compared to $18.2 million for the same period in 2024.
• As of March 31, 2025, Tyra Biosciences had cash, cash equivalents, and marketable securities totaling $318.9 million.
• The company believes its current financial resources will be sufficient to fund operating expenses and capital expenditures through at least 2027.
• Tyra Biosciences terminated its 2022 sales agreement with Virtu Americas LLC and entered into a new sales agreement with TD Securities (USA) LLC in May 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is experiencing increased losses, it has sufficient cash to fund operations through 2027 and is making progress with its clinical programs. The potential capital raise introduces uncertainty but also provides flexibility.

Positives

• The company's cash position of $318.9 million is expected to fund operations through at least 2027.
• Clinical trials for TYRA-300, TYRA-200, and TYRA-430 are progressing.
• The company reported positive interim data from the SURF301 study in late October 2024.
• The company has commenced patient dosing in the TYRA-430 study in April 2025.
• The company has a precision medicine platform, SNP, that enables rapid and precise drug design.

Negatives

• The company reported a net loss of $28.1 million for Q1 2025, an increase from the $18.2 million loss in Q1 2024.
• The company has not generated any revenue to date and does not expect to generate any revenue from product sales unless and until it successfully completes the development of and obtains regulatory approval for its product candidates, which will not be for several years, if ever.
• The company has incurred significant operating losses since inception.

Risks

• The company's future capital requirements will depend on many factors, including the outcome of regulatory review of current or future product candidates.
• The company may be unable to raise additional funds or enter into collaborations when needed on favorable terms or at all.
• The company's forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.
• The company's research and development expenses may vary significantly based on a wide variety of factors.

Future Outlook

Based on the current operating plan, the company believes that its cash, cash equivalents and marketable securities as of March 31, 2025 will be sufficient to fund its operating expenses and capital expenditures through at least 2027.

Industry Context

Tyra Biosciences is operating in the competitive biotechnology industry, focusing on precision medicines for targeted oncology and genetically defined conditions. The company's focus on FGFR biology and its SNP platform positions it to address unmet needs in areas like bladder cancer, skeletal conditions, and intrahepatic cholangiocarcinoma.

Comparison to Industry Standards

• It's difficult to compare Tyra's results directly to industry standards without knowing the specific details of their clinical programs and development stage.
• However, other biotechnology companies in similar stages of development, such as Relay Therapeutics and Black Diamond Therapeutics, also focus on precision oncology and face similar challenges in terms of funding, clinical trial execution, and regulatory approvals.
• For example, Relay Therapeutics, which focuses on developing precision medicines for genetically defined cancers, reported research and development expenses of $53.4 million for the first quarter of 2024.
• Black Diamond Therapeutics, another precision oncology company, reported research and development expenses of $14.7 million for the same period.
• Tyra's research and development expenses of $24.964 million for the three months ended March 31, 2025, are within the range of these comparable companies, but the specific programs and development stages need to be considered for a more accurate comparison.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's ability to fund operations through 2027 provides job security for employees.
• Patients: Successful development of the company's product candidates could provide new treatment options for patients with cancer and skeletal conditions.

Next Steps

• Dose the first child in the BEACH301 study in the second quarter of 2025.
• Dose the first patient in the SURF302 study in the second quarter of 2025.
• Continue dose optimization in the SURF301 study.
• Continue evaluating TYRA-200 in the SURF201 Phase 1 clinical study.
• Continue evaluating TYRA-430 in the SURF431 Phase 1 clinical study.

Key Dates

Keywords

TYRA Biosciences, financial results, clinical trials, FGFR, TYRA-300, TYRA-200, TYRA-430, biotechnology, oncology, precision medicine